WO2017153958A1 - Nouvelles formes polymorphes et forme amorphe d'olaparib - Google Patents

Nouvelles formes polymorphes et forme amorphe d'olaparib Download PDF

Info

Publication number
WO2017153958A1
WO2017153958A1 PCT/IB2017/051407 IB2017051407W WO2017153958A1 WO 2017153958 A1 WO2017153958 A1 WO 2017153958A1 IB 2017051407 W IB2017051407 W IB 2017051407W WO 2017153958 A1 WO2017153958 A1 WO 2017153958A1
Authority
WO
WIPO (PCT)
Prior art keywords
olaparib
oiaparib
crystalline form
amorphous
preparation
Prior art date
Application number
PCT/IB2017/051407
Other languages
English (en)
Inventor
Lalitkumar Dilipsing RAJPUT
Radhakrishna Bhikaji SHIVDAVKAR
Gurvinder Pal Singh
Purna Chandra Ray
Girij Pal Singh
Original Assignee
Lupin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Limited filed Critical Lupin Limited
Publication of WO2017153958A1 publication Critical patent/WO2017153958A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to the novel crystalline and amorphous forms of Olaparib, their methods of preparation and pharmaceutical compositions comprising said crystalline and amorphous forms.
  • Olaparib is chemically known as 4-[3 - ⁇ 4-ey copropane butaxycarbonylpiperizine-1 - carbonyl)-4-fluorobenzyl]-2M-phthaIazi.n- 1 -ketone, can be used to provide a pofy-ADP- ribose polymerase (PARP) inhibitor action.
  • PARP pofy-ADP- ribose polymerase
  • This effect can be used for the treatment of cancer, such as breast cancer or ovarian cancer, which can be particularly effective in the treatment of the cells in the homologous recombination (HR) dependent DMA double- stranded break (DSB) repair pathway.
  • HR homologous recombination
  • DSB homologous recombination
  • BRCA I N .007295.
  • BRCA 2 NM_000059 hereditary breast/ovarian cancer genes are just 2 out of many proteins in the HR dependent DNA DSB repair pathway.
  • PCT Publication No. WO2G08/047082 which is hereby incorporated by reference, discloses crystalline form A and process for the preparation thereof.
  • PCX Publication No. WO2009 050469 which is hereby incorporated by reference, discloses crystalline form L and process for the preparation thereof.
  • POT Publication No. WO2010/04105 1 describes Olaparib in a solid dispersion with a matrix polymer.
  • Polymorphism is the ability of a compound to exist in two or more different crystalline phases thai differ in arrangement of the molecules in crystal lattice. Although polymorphs have the same chemical composition, they differ in packing and geometrical arrangement. and exhibit different physical properties such as melting point. X-ray diffraction patterns, density, stability, and solubility.
  • Figure 1 1 Illustrates X-ray powder diffraction pattern of crystalline Form M of Olaparib.
  • Figure 4 Ill ustrates X-ray powder diffraction pattern of amorphous Form of Olaparib.
  • Figure 5 Differential Scanning Calorimetry thermogram of amorphous Form of Olaparib.
  • Figure 6 Thermogravi metric analysis curve of amorphous Form of Olaparib. Summary of the. invention:
  • the present invention provides a stable crystalline Form M of Olaparib with XPRD as shown herein in Figure 1.
  • the invention provides a process for the preparation of crystalline Form of Olaparib.
  • the invention provides a pharmaceutical composition comprising said stable crystalline Form M and at least one pharmaceutically acceptable excipient or carrier.
  • the present invention provides an amorphous form of Olaparib, In another aspect, the invention provides a process for the preparation of an amorphous form of Olaparib.
  • the invention provides a pharmaceutical composition comprising said amorphous form and at least one pharmaceutically acceptable excipient or carrier.
  • excipient or “pharmaceutically acceptable excipient * ' means a component of a pharmaceutical product that is not an active ingredient and includes but not limited to fillet; diluent, disintegrants. glidants, stabilizers, surface active agents etc.
  • excipients that are useful in preparing a pharmaceutical composition are generally safe, non-toxic and neither biologically nor otherwise undesirable, and are acceptable for veterinary use as well as human pharmaceutical use.
  • One excipient can perform more than one function.
  • the term “stable” herein means crystall ine form that substantially does not convert to any other solid form.
  • the present invention provides a stable crystalline Form M of Olaparib.
  • the present invention provides a crystalline Form M of Olaparib, which is characterized by XRPD (X-ray powder dtffractogram) which comprises of peaks expressed as 2 ⁇ at J 0.25, 13.27, 13.97, 17,45, 20.68, 22.06, 23.3 1. 25.61 , 28.99 ⁇ 0.2 degrees.
  • the XRPD of crystalline Form of Oiapan ' b is depicted in figure 1.
  • the present invention provides a process for the preparation of a crystalline Form M of Olaparib. which comprises the steps of: i) stirring a mixture Olaparib and n-heptane solvent; ii) isolating the crystalline Form M of O!aparib.
  • step ( i) is carried our at a temperature of about 0 to about 70°C.
  • step (ii) The isolation of crystalline Olaparib of step (ii) could be done by conventional techniques known to a person skilled in the art such as fi ltration, centrifugati n etc.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising Form M of crystalline Olaparib with pharmaceutically acceptable exeipients.
  • the Form M. of crystalline Olaparib can be formulated into various pharmaceutical compositions like powder, granules, capsules, tablets, pellets etc.
  • the pharmaceutical composition of the invention can be formed by various methods known in the art such as by dr granulation, wet granulation, melt granulation, direct compression, double com ression, extrusion spheromzatton, layering and the like.
  • the composition or formulation may be coated or uncoated. Coati ng of compositions such as tablets and capiets is well known in the art.
  • liquid formulations such as oral solutions may offer a suitable alternative, avoiding the need of swallowing tablets or capsules.
  • An oral solution further provides the possibility of a more flexible closing regimen.
  • the superior solubility of Form M of crystalline Olaparib of 'the present invention makes this particular solid state form especially suitable for the preparation of liquid pharmaceutical formulations such as oral solutions.
  • Form M of crystalline Olaparib into the final pharmaceutical dosage forms and include, for example, any one or more of diluents, binders, stabilizers, lubricants, glidants, disintegrating agents, surfactants, and other additives thai are commonly used in solid pharmaceutical dosage form preparations.
  • the present invention includes crystalline Form M of Olaparib may be used in the preparation of a medicament for the treatment of cancer which is deficient in Homologous Recombination (HR) dependent DMA DSB repair activity, or in the treatment of a patient of a cancer which is deficient in HR dependent DNA DSB repair activity, comprising administering to said patient a therapeuticaiiy-effective amount of the compound.
  • the present invention provides an amorphous form of Olaparib.
  • the XPRD of amorphous form of Olaparib is depicted in fig 4.
  • the invention provides a process for preparation of an amorphous form of Olaparib comprising, the steps of:
  • step a) providing a solution of Olaparib in one or more solvents; and b) obtaining the amorphous form of Oiaparib by removal of solvent ' s).
  • the solvent employed in step a) is selected from the group consisting of water, ' methanol, ethanol, isopropanol, 2-propanol, 1 -butanoi, t-batyl alcohol, 1 - pentano!, 2-pentanol, amyl alcohol ethylene glycol, glycerol, acetone, butanone, 2-peiitanone, 3-pentartone, methyl butyl ketone, methyl isobuiyl ketone, ethyl formate, methyl acetate, ethyl acetate, propyl acetate, t-butyl acetate, isobuiyl acetate, toluene, xylene, methylene dichioride, ethylene dichioride, chlorobenzen
  • Step b) involves isolation of an amorphous form of Olaparib from the solution of step a).
  • The- isolation may be affected by removing the solvent! s).
  • Suitable techniques which may be used for the removal of solvent include using a rotational distillation device such as a rotary evaporator ⁇ e.g., Buchi Rotavapor), spray drying, agitated thin film drying ("ATFD”). freeze drying (iyophihzation), and the like or any other suitable technique.
  • isolation can be effected by addition of suitable anti-solvent to the solution obtain in step a), optionally by concentrating the solution obtained in step a).
  • suitable anti-solvents that may be used can be selected from one or more of hydrocarbons like hexanes, n-heptane, n- pen lane, cyelohexane, merh !cyciohexane and the like: aromatic hydrocarbons like toluene, xylene, ethylbenzene and the like: ethers like diethyl ether, diisopropyl ether, t-butyl methyl ether, dibutyl ether, tetrahydrofuran, i ,4-dioxane. 2- rnethoxyethonol and the like or water.
  • the present invention provides a pharmaceutical composition comprising an amorphous form of Olaparib.
  • the amorphous form of Olaparib can be formulated into various pharmaceutical compositions like powder, granules, capsules, tablets, pellets etc.
  • compositions of the invention can be formed by various methods known in the art such as by dry granulation, wet granulation, melt granulation, direct compression, double compression, extrusion spheronization, layering and the like.
  • the composition or formulation may be coated or imcoated. Coating of compositions such as tablets and caplets is well known in the art.
  • liquid formulations such as oral solutions may offer a suitable alternative, avoiding the need of swallowing tablets or 2017/051407
  • a n oral solution further provides the possibility of a more flexible dosing regimen.
  • the superior solubility of the amorphous form of Olapavib of the present invention makes this particular solid state form especially suitable for the preparanon of liquid pharmaceutical formulations such as oral solutions.
  • compositions may be utilized as required for conversion of the amorphous form of Olaparib into the final pharmaceutical dosage forms and include, for example, any one or more of diluents, binders, stabilize rs, lubricants, glidants, disintegrating agents, surfactants, and other additives that are commonly used in solid pharmaceutical dosage form preparations.
  • the present invention provides the use of a crystalline Form M of Olaparib in the preparation of a medicament for the treatment of cancer which, is deficient in Homologous Recombination (HR) dependent DNA DSB repair activity, or in the treatment of a patient of a cancer which is deficient in HR dependent DMA DSB repair activity, comprising administering to said patient a therapeutically effective amount of the com ound.
  • HR Homologous Recombination
  • the diluents, binders, bulking agents, stabilizers, lubricants, glidants, disintegrating agents, surfactants, and other additives that are commonly used in sol id pharmaceutical dosage form preparations Includes Diluents :
  • Various useful fillers or diluents include but are not limited to starches, lactose, mannitoi (Pea.rlitoi fM SD200 ), cellulose derivatives, confectioner's sugar and the like.
  • Different grades of lactose include but are not limited to lactose monohydrate, lactose DT (direct tableting), lactose anhydrous, Flowkic i ! . Pharinatose f3 ⁇ 4i and others.
  • starches include but are not limited to maize starch, potato starch, rice starch, wheat starch, pregelatinized starch and starch J 500, starch 1500 LM grade ⁇ low moisture content grade) from Coloreon, fully pregelaiinized starch and others.
  • Different cellulose compounds that can be used include crystalline celluloses and powdered celluloses. Examples of crystalline cellulose products include bui are not limited to CEOLUSTM G801 . A vice!TM PHI 01 , PHI 02, PH301 , PH302 and PH-F20, PH I 12 micToerysta!lme cellulose 1 14, and microcrystalJine cellulose i 12.
  • diluents include but are not limited to caimellose, sugar alcohols such as mannitol (Pearlitol 5 M SD200). sorbitol and xylitol, calcium carbonate, magnesium carbonate, dibasic calcium phosphate, and trtbasic calcium phosphate.
  • binders include but are not limited to hydroxypropylceUuloses. also called HPC ⁇ lucelTM LF. lucel EXF) and useful in various grades, hydroxy propyl roethylce!luioses. also called hypromei loses or HPMC (MethocelTM) and useful in. various grades, polyvinylpyrrolidones or povidones (such as grades PVP-K25, PVP- 29, PVP- 30, and PVP-K90).
  • PiasdoneTM S-630 copovidone
  • powdered acacia gelatin, guar gum, carbomers (Carbopol ! M )
  • methyleeliuioses polymethacrylates, and starches.
  • Bulking agents are ingredients which may provide bulk to a pharmaceutical composition.
  • Various useful binders include but are not lim ited to PEG s, mannitol, trehalose, lactose, sucrose, polyvinyl pyrrol idone, sucrose, glycine, cyclodexirins, dextran and derivatives and mixtures thereof.
  • crospovidones examples of commercially available crospovidone products including but not limited to crossl inked povidone, ollidonTM CL, PoiypiasdoneTM XL, XI- 10, and INF- 10 and low-substituted hydroxypropyicelluioses.
  • low-substituted ' hydroxypropyicelluloses incl ude but are not limited to low-substituted hydroxypropyiceikiiose LH1 i , 1..H2 L LH31 , LH22, LH32, LH.20, LH3G, LH32 and LH33.
  • Other useful disintegrants include .sodium starch giycolate, colloidal silicon dioxide, and starches.
  • Various useful stabilizers include basic inorganic salts, such as but not limited to basic, inorganic salts of sodium, potassium, magnesium and calcium.
  • basic inorganic salts of sodium are sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, and the like.
  • basic inorganic salts of potassium are potassium carbonate, potassium hydrogen carbonate, potassium hydroxide, and the like.
  • basic, inorganic salts of magnesium are heavy magnesium carbonate, magnesium carbonate, magnesium oxide, magnesium hydroxide, magnesium metasificate aluni .
  • magnesium silicate magnesium alaminate
  • synthetic hydrotalcite [M f tAk(OH)i*.C0 3 .4H20]
  • aluminum hydroxide-magnesium [2.5MgO.Al ⁇ ⁇ 3 ⁇ 4.xH 2 0 ⁇ . and the like.
  • basic inorganic salts of calcium include precipitated calcium carbonate, calcium hydroxide, and the like.
  • Useful surface-active agents include non-tonic, ca iontc and anionic surface-active agents.
  • Useful non-ionic surface-active agents include ethylene glycol stearates, propylene glycol stearates, diethylene glycol stearates, glycerol stearates, sorbitan esters (SPANTM) and polyhydroxyethyienicaSl treated sorbitan esters (TWEEN £M ), aliphatic alcohols and PEG ethers, phenol and PEG ethers.
  • Useful eationk surface-active agents include quaternary ammonium salts (e.g. cetyltrsmethylammoniura bromide) and amine salts (e.g.
  • octadecyiamine hydrochloride Useful anionic surface-active agents include sodium stearate, potassium stearate, ammonium stearaie, and calcium stearate, triethenolamine stearate. sodium iauryl sulphate, sodium dioctylsuiphosuccinate, and sodium dodeeylbenzenesulphonate. Natural surface-active agents may also be used, such as for example phospholipids, e.g.
  • diacyiphosphaiidyl glycerols diaceylphosphatidyl cholines, and diaceylphosphatidic acids, the precursors and derivatives thereof, such as for example soybean lecithin and egg yo!k.
  • any pharmaceutically acceptable tabieting lubricant can be added to assist with compressing tablets.
  • Useful tablet lubricants include magnesium stearate, glyceryl monostearates, palmitic acid, talc, ca nauba wax, calcium stearate sodium, sodium or magnesium iauryl sulfate, calcium soaps, zinc srearate, polyoxyethylsoe monostearates. calcium .silicate, silicon dioxide, hydrogenated vegetable oils and fats, stearic acid and combinations thereof.
  • One or more glidant materials which improve the flow of powder blends and minimize dosage form weight variations can be used.
  • Useful glidants include but are not limited to silicone dioxide, talc and combinations thereof. Coloring Agents;
  • Coloring agents can be used to color code the compositions, for example., to indicate the type and dosage of the therapeutic, agent therein.
  • Suitable coloring agents include, without limitation, natural and/or artificial compounds such as FD&C coloring agents, natural juice concentrates, pigments such as titanium oxide, silicon dioxide, iron oxides, zinc oxide, combinations thereof, and the. like.
  • Useful additives for coatings include but are not limited to plasticizers. antiadherents, opacifiers, solvents, and optionally colorants, lubricants, pigments, ant ' tfoam agents, and polishing agents.
  • plasticizers include but are not limited to substances such as castor oil diacetyiated monoglycerides, dibutyl. sehacate. diethyl phthaiate, glycerin, polyethylene glycol, propylene glycol, triacetin, a trtethyi citrate. Also, mixtures of plastic izers may be utilized. The type of plasticizer depends upon the type of coating agent. An opacifier like ti fianium dioxide may also be present, typically in an amount ranging from about 10% to about 20% based, on the total weight of the coa ting.
  • Example 1 Preparation of amorphous form ' of Olaparib:
  • Olaparib 10.0 gm of Olaparib was dissolved in 50 ml of DMF at S0-60°C and cooled to room temperature. 500 mi of water was taken in to round bottom flask at 25-30°C and stirred, DMF sofution of Olaparib was added to above water dropwise at 25*30°C and stirred for 2 hoars. The resulting solid was filtered and dried in oven under vacuum to get 9.2 gm of desired compound.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une forme cristalline M d'olaparib, une forme amorphe d'olaparib, un procédé pour leur préparation, une composition pharmaceutique de ceux-ci et leur utilisation comme médicaments. 5
PCT/IB2017/051407 2016-03-11 2017-03-10 Nouvelles formes polymorphes et forme amorphe d'olaparib WO2017153958A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621008662 2016-03-11
IN201621008662 2016-03-11

Publications (1)

Publication Number Publication Date
WO2017153958A1 true WO2017153958A1 (fr) 2017-09-14

Family

ID=58544991

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/051407 WO2017153958A1 (fr) 2016-03-11 2017-03-10 Nouvelles formes polymorphes et forme amorphe d'olaparib

Country Status (1)

Country Link
WO (1) WO2017153958A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10662178B2 (en) 2018-01-31 2020-05-26 Apotex Inc. Crystalline form of Olaparib
CN111718300A (zh) * 2019-06-18 2020-09-29 台湾神隆股份有限公司 奥拉帕尼新晶型和其制备方法
WO2021044437A1 (fr) 2019-09-04 2021-03-11 Cipla Limited Co-cristaux d'olaparib et leur procédé de préparation
WO2021220120A1 (fr) 2020-04-28 2021-11-04 Rhizen Pharmaceuticals Ag Nouveaux composés utiles en tant qu'inhibiteurs de la poly(adp-ribose) polymérase (parp)
CN113636979A (zh) * 2021-08-12 2021-11-12 天津理工大学 一种奥拉帕尼与富马酸共晶晶型α及其制备方法与应用
WO2022090938A1 (fr) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Dérivés de phtalazinone utiles en tant qu'inhibiteurs de parp
WO2022215034A1 (fr) 2021-04-08 2022-10-13 Rhizen Pharmaceuticals Ag Inhibiteurs de la poly(adp-ribose) polymérase

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047082A2 (fr) * 2006-10-17 2008-04-24 Kudos Pharmaceuticals Limited Dérivé de phtalazinone
WO2009050469A1 (fr) * 2007-10-17 2009-04-23 Kudos Pharmaceuticals Limited 4-[3-(4-cyclopropanecarbonylpipérazin-1-carbonyl)-4-fluorobenzyl]-2h-phtalazin-1-one
CN105254572A (zh) * 2015-11-09 2016-01-20 北京科莱博医药开发有限责任公司 一种奥拉帕尼的晶型及其制备方法和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047082A2 (fr) * 2006-10-17 2008-04-24 Kudos Pharmaceuticals Limited Dérivé de phtalazinone
WO2009050469A1 (fr) * 2007-10-17 2009-04-23 Kudos Pharmaceuticals Limited 4-[3-(4-cyclopropanecarbonylpipérazin-1-carbonyl)-4-fluorobenzyl]-2h-phtalazin-1-one
CN105254572A (zh) * 2015-11-09 2016-01-20 北京科莱博医药开发有限责任公司 一种奥拉帕尼的晶型及其制备方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954, ISSN: 0340-1022, DOI: 10.1007/3-540-69178-2_5 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10662178B2 (en) 2018-01-31 2020-05-26 Apotex Inc. Crystalline form of Olaparib
CN111718300A (zh) * 2019-06-18 2020-09-29 台湾神隆股份有限公司 奥拉帕尼新晶型和其制备方法
EP3986870A4 (fr) * 2019-06-18 2023-07-12 ScinoPharm Taiwan, Ltd. Nouvelle forme cristalline d'olaparib et procédé de préparation associé
WO2021044437A1 (fr) 2019-09-04 2021-03-11 Cipla Limited Co-cristaux d'olaparib et leur procédé de préparation
WO2021220120A1 (fr) 2020-04-28 2021-11-04 Rhizen Pharmaceuticals Ag Nouveaux composés utiles en tant qu'inhibiteurs de la poly(adp-ribose) polymérase (parp)
WO2022090938A1 (fr) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Dérivés de phtalazinone utiles en tant qu'inhibiteurs de parp
WO2022215034A1 (fr) 2021-04-08 2022-10-13 Rhizen Pharmaceuticals Ag Inhibiteurs de la poly(adp-ribose) polymérase
CN113636979A (zh) * 2021-08-12 2021-11-12 天津理工大学 一种奥拉帕尼与富马酸共晶晶型α及其制备方法与应用

Similar Documents

Publication Publication Date Title
WO2017153958A1 (fr) Nouvelles formes polymorphes et forme amorphe d'olaparib
EP2760821B1 (fr) Sel de choline d'un composé anti-inflammatoire à base de cyclobutènedione substitué
WO2006118329A1 (fr) Préparation de type émulsion stable
WO2008072534A1 (fr) Préparation médicale sous forme solide contenant un mannitol ou un lactose
CA2703971A1 (fr) Suspension pediatrique stabilisee de carisbamate
JPWO2010113840A1 (ja) ソリフェナシン非晶質体を含有した固形医薬組成物
JP2018515520A (ja) ボルチオキセチンピログルタミン酸塩
KR20150123248A (ko) 유기 화합물의 제제
JP2020518611A (ja) 水溶解度及びバイオアベイラビリティが改善された組成物
KR102276281B1 (ko) 의약으로 사용하기 위한 펄린돌 광학이성질체의 약학적으로 허용가능한 염
RU2288218C2 (ru) Формы гатифлоксацина для применения в педиатрии
AU2004238537A1 (en) Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
US20150328215A1 (en) Stable amorphous raltegravir potassium premix and process for the preparation thereof
JP2001503734A (ja) カリウム、ナトリウムおよびトリスオキサプロジン塩医薬組成物
CN109316451B (zh) 治疗高血压和相关疾病的口服固体制剂
KR20110005974A (ko) 인도부펜 및 그 광학적 이성질체의 서방성 제제 및 그 광학적 이성질체의 분리방법
WO2016001093A1 (fr) Procédé de préparation de diméthylfumarate microcristallin
JP2002212063A (ja) コポリビドン含有製剤
EP3981470A1 (fr) Préparation à enrobage entérique comprenant un inhibiteur de xanthine oxydase
CN101230069B (zh) 新的头孢菌素衍生物
CN101663035A (zh) 4－环丙基甲氧基－n－(3,5－二氯代－1－环氧－吡啶－4－基)－5－(甲氧基)吡啶－2－甲酰胺用于治疗与帕金森症有关的运动障碍的用途
WO2018078536A1 (fr) Dispersion solide stable de sofosbuvir et procédé de préparation de cette dispersion
JP3281872B2 (ja) ７−イソインドリン−３−キノリンカルボン酸の塩、その水和物およびそれらを活性成分とする組成物
CN116528840A (zh) 细胞内atp增强剂
JP2020152707A (ja) 安定化されたエソメプラゾールマグネシウム水和物含有腸溶性固形製剤

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17717237

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17717237

Country of ref document: EP

Kind code of ref document: A1